Therefore, the use of CNF1 modulating multiple FAK-regulated pathways for bone regeneration, including the Wnt/β-catenin pathway, may become a new target in the development of novel therapeutics for astronauts at risk of OBD inhibition and bone loss, and for clinical patients with osteoporosis. Here, PTK2 is linked to osteoporosis.